NCT04001634View on ClinicalTrials.gov

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

CompletedOBSERVATIONAL

Enrollment

285

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

May 15, 2019

Study Completion Date

August 15, 2020

Conditions

Breast Cancer

Trial Locations (1)

200032

Biyun Wang, MD, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT04001634 - Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC | Biotech Hunter | Biotech Hunter